Overview

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca